Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure

Hemodialysis International

Volumn 14, Issue 3, 2010, Pages 295-301

  Pereira, Rui ^a,b   Costa, Elísio ^c,d   Gonçalves, Marta ^e   Miranda, Vasco ^f   Sameiro Faria, Maria do ^f   Quintanilha, Alexandre ^a,d   Belo, Luís ^a,d   Lima, Margarida ^e   Santos Silva, Alice ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b Porto Regional Center of Portuguese Institute of Blood   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^e Centro Hospitalar Universitario do Porto   (Portugal)

^f Fresenius Medical Center   (Portugal)

Author keywords

Monocyte activation; Neutrophil activation; Resistance; RhEPO therapy

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; HLA DR ANTIGEN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL SURFACE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; MALE; MONOCYTE ACTIVATION; PROTEIN EXPRESSION; THERAPY RESISTANCE; TREATMENT RESPONSE;

EID: 77955069593     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00450.x     Document Type: Article

References (29)

1. Kerr PG. Renal anaemia: Recent developments, innovative approaches and future directions for improved management. Nephrology 2006, 11:542-548.
2. Macdougall IC. Present and future strategies in the treatment of renal anaemia. Nephrol Dial Transplant 2001, 16((Suppl 5)):50-55.
3. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002, 17((Suppl 11)):39-43.
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998, 32((Suppl 3)):S112-S119.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996, 28:53-61.
6. Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents-what do we know and what needs to be clarified? Nephrol Dial Transplant 2005, 20((Suppl 8)):2-viii7.
7. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-γ, TNF-α, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003, 14:1776-1784.
8. Macdougal IC. Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 1995, 10:607-614.
9. Drueke TB. R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 1995, 10((Suppl 2)):S62-S68.
10. Danielson B. R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 1995, 10((Suppl 2)):S69-S73.
11. Fishbane S. Hyporesponsiveness to recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2000, 29:545-548.
12. Schindler R, Senf R, Frei U. Influencing the inflammatory response of haemodialysis patients by cytokine elimination using large-pore membranes. Nephrol Dial Transplant 2002, 17:17-19.
13. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999, 33:63-72.
14. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fc gamma receptors in end-stage renal disease. N Engl J Med 1990, 322:717-722.
15. Costa E, Lima M, Alves JM. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008, 28:268-275.
16. Costa E, Lima M, Rocha S. IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells Mol Dis 2008, 41:134-135.
17. Costa E, Rocha S, Rocha-Pereira P. Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol 2008, 28:935-940.
18. Locatelli F, Aljama P. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004, 19((Suppl 2)):1-ii47. European Best Practice Guidelines Working Group.
19. Levin RD, Kwaan HC, Ivanivich P. Changes in platelet functions during hemodialysis. J Lab Clin Med 1978, 92:779-786.
20. Craddock PR, Fehr J, Brigham KL, Kronemberg RS, Jacob HS. Complement and leukocyte mediated pulmonary dysfunction in hemodialysis. N Eng J Med 1977, 296:769-774.
21. Craddock PR, Hammerschmidt DE, White JG, Dalmasso AP, Jacob HS. Complement (C5a)-induced granulocyte aggregation in vitro: A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 1977, 60:260-264.
22. Dolegowska B, Kwiatkowska E, Wesolowska T, Bober J, Chlubek D, Ciechanowski K. Effect of hemodialysis on the content of fatty acids in monolayers of erythrocyte membranes in patients with chronic renal failure. Renal Fail 2007, 29:447-452.
23. Brimble KS, McFarlane A, Winegard N, Crowther M, Churchill DN. Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc 2006, 34:411-420.
24. Pay S, Musabak U, Simşek I. Expression of CXCR-1 and CXCR-2 chemokine receptors on synovial neutrophils in inflammatory arthritides: Does persistent or increasing expression of CXCR-2 contribute to the chronic inflammation or erosive changes? Joint Bone Spine 2006, 73:691-696.
25. Sherry B, Dai WW, Lesser ML, Trachtman H. Dysregulated chemokine receptor expression and chemokine-mediated cell trafficking in pediatric patients with ESRD. Clin J Am Soc Nephrol 2008, 3:397-406.
26. Yamasaki H, Nishi H, Nagake Y, Mino Y, Makino H. Changes in CD14 expression on monocytes and changes in soluble CD14 level during hemodialysis. Clin Exp Nephrol 2000, 4:58-62.
27. Dasselaar JJ, Hooge MNL, Pruim J. Relative blood volume changes underestimated total blood volume changes during hemodialysis. Clin J Am Soc Nephrol 2007, 2:669-674.
28. Yu AW, Nawab ZM, Barnes WE, Lai KN, Ing TS, Daugirdas JT. Splanchnic erythrocyte content decreases during hemodialysis: A new compensatory mechanism for hypovolemia. Kidney Int 1997, 51:1986-1990.
29. Costa E, Rocha S, Rocha-Pereira P. Changes in red blood cells membrane protein composition during hemodialysis procedure. Ren Fail 2008, 30:971-975.